 The main aim of this trial is to compare improvement of patients fatigue status between patients with different doses of PG2 treatment. Patients fatigue status will be assessed by the Brief Fatigue Inventory-Taiwanese BFI-T Form. Each patients fatigue improvement response will be defined as an improvement in the mean fatigue scores by at least 10 from baseline. Other quality of life parameters will be measured by the 11 questions SS11 of the EORTC QLQ-C30 and by Karnofsky performance scale. Patients weight change and its related c-reactive protein will be followed. There are two study arms in this trial: 1 the PG2 High Dose arm; and 2 the PG2 Low Dose arm. 